Last reviewed · How we verify
NCT06027775
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
trial testing Targeted agent in Colorectal Cancer Metastatic in 198 participants. Completed in 1 January 2023.
1 January 2023
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 198 |
| Start date | 1 January 2013 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 January 2023 |
Drugs / interventions tested
- Targeted agent — full drug profile →
Conditions studied
- Colorectal Cancer Metastatic — all drugs for Colorectal Cancer Metastatic →
Sponsor
Fudan University
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with KRAS/NRAS/BRAF mutated tumors or cycle of conversion therapy ≤ 4 can benefit more from chemotharapy plus targeted therapyrather than from chemotharapy alone, with a tolerable toxicity profile.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study.
Chang W, Zhou S, Guan X, Xu D, et al · · 2025 · PMID 41282550 · DOI 10.1093/gastro/goaf098
Verify or expand the search:
- PubMed search for NCT06027775
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer Metastatic
Currently open trials in the same condition.
- NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
- NCT07462650 — Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer · Phase 1, PHASE2 · recruiting
- NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
- NCT07172282 — INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases · EARLY_PHASE1 · recruiting
- NCT06889610 — A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. · Phase 2 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06027775 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 7 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027775.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing